encorafenib,binimetinib
pierre fabre,ono pharma,pfizer
['pharos', 'binimetinib', 'encorafenib', 'nsclc', 'sclc']
encorafenib plus binimetinib in metastatic nsclc with braf mutation. phase 2 pharos study .good response rate and pfs . #asco23 
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists